Version 1
: Received: 23 January 2024 / Approved: 24 January 2024 / Online: 24 January 2024 (13:39:51 CET)
How to cite:
Urso, A.; Martino, E.A.; Cuneo, A.; Gentile, M.; Rigolin, G.M. Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel Drugs. Preprints2024, 2024011747. https://doi.org/10.20944/preprints202401.1747.v1
Urso, A.; Martino, E.A.; Cuneo, A.; Gentile, M.; Rigolin, G.M. Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel Drugs. Preprints 2024, 2024011747. https://doi.org/10.20944/preprints202401.1747.v1
Urso, A.; Martino, E.A.; Cuneo, A.; Gentile, M.; Rigolin, G.M. Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel Drugs. Preprints2024, 2024011747. https://doi.org/10.20944/preprints202401.1747.v1
APA Style
Urso, A., Martino, E.A., Cuneo, A., Gentile, M., & Rigolin, G.M. (2024). Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel Drugs. Preprints. https://doi.org/10.20944/preprints202401.1747.v1
Chicago/Turabian Style
Urso, A., Massimo Gentile and Gian Matteo Rigolin. 2024 "Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel Drugs" Preprints. https://doi.org/10.20944/preprints202401.1747.v1
Abstract
Novel drugs profoundly changed the outcomes in CLL patients and traditional prognostic/predictive factors that were delineated in the era of chemo-immunotherapy need to be validated in the contest of these new targeted therapies. Currently, the most important prognostic genetic biomarkers are immunoglobulin heavy chain variable (IGHV) mutational status, genetic aberrations including del(17p)/TP53 abnormalities and the complex karyotype. In this review we discuss the prognostic/predictive role of these genetic markers in relation to novel treatments. Moreover, we present and discuss the new score systems that were elaborated and validated in the era of new drugs. Given the deeper responses obtained with small molecules, new prognostic/predictive markers, including measurable residual disease, and validated prognostic scores could possibly be incorporated into routine prognostic scores, to better identify “very-high” CLL patients, who will need more effective treatments.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
